Under the direction of the BREATH scientist Prof. Dr. Burkhard Tümmler, the second edition of the monograph „Mutation-specific therapies in cystic fibrosis“ has now been published.
With triple therapy, the lungs of cystic fibrosis patients are better ventilated down to their most minor ramifications.
Scientists at the DZL and Charité have found that a new triple therapy improves treatment outcomes for a common form of cystic fibrosis.
DZL researchers have discovered how airway obstruction promotes inflammatory responses that are part of the disease picture in cystic fibrosis and chronic obstructive pulmonary disease (COPD).
Regular examination of the lungs using magnetic resonance imaging (MRI) can detect how lung disease develops in children with cystic fibrosis.
A clinical trial has shown that a triple combination therapy consisting of three known compounds is both safe and effective in cystic fibrosis patients with relatively rare disease-causing genetic defects.
Every year, DZL allocates part of its budget to innovative clinical trials that are based on initiatives by DZL scientists (Investigator Initiated Trials). Four more trials, which will be described more specifically hereinafter, will be...